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Background: Autophagy is a cellular response to intracellular pathogens including mycobacteria and is induced by
the direct inhibitors of mammalian target of Rapamycin (mTOR), a major negative regulator of autophagy.
Autophagy induction by mTOR inhibition (mTOR dependent autophagy), through chemical means or starvation,
leads to mycobacterial killing in infected cells. However, previous work by our group has shown that mycobacterial
infection of macrophages naturally induces both autophagy and mammalian target of Rapamycin (mTOR) activity
(mTOR independent autophagy). In the current work, we further explore the relationship between mTOR activity
and mycobacterial killing in macrophages.
Results: While low concentrations of the mTOR inhibitors, Rapamycin, Torin 1, and Torin 2, can effectively reduce or
block mTOR activity in response to lipopolysaccharides (LPS) or mycobacteria, higher concentrations (10 uM) are
required to observe Mycobacterium smegmatis killing. The growth of M. smegmatis was also inhibited by high
concentrations of Rapamycin in LC3B and ATG5 deficient bone marrow derived macrophages, suggesting that
non-autophagic mechanisms might contribute to killing at high doses. Since mycobacterial killing could be
observed only at fairly high concentrations of the mTOR inhibitors, exceeding doses necessary to inhibit mTOR, we
hypothesized that high doses of Rapamycin, the most commonly utilized mTOR inhibitor for inducing autophagic
killing, may exert a direct bactericidal effect on the mycobacteria. Although a short-term treatment of mycobacteria
with Rapamycin did not substantially affect mycobacterial growth, a long-term exposure to Rapamycin could impact
mycobacterial growth in vitro in select species.
Conclusions: This data, coupled with previous work from our laboratory, further indicates that autophagy induction
by mTOR inhibition is an artificial means to increase mycobacterial killing and masks more relevant endogenous
autophagic biochemistry that needs to be understood.
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The autophagy pathway was first identified as a stress re-
sponse that allowed cells to survive when nutrients were
scarce [1]. Under such conditions, the lack of amino acids
and other basic building blocks leads to a reduction in
mTOR signaling, a critical sensor of nutrient availability* Correspondence: sunhee.lee@duke.edu
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unless otherwise stated.[2]. The absence of mTOR activity induces a reduction in
anabolic activities such as protein synthesis, and autoph-
agy is induced to digest unwanted cellular material and
liberate building blocks that can be used to sustain sur-
vival. The induction of autophagy in response to reduced
mTOR signaling due to nutrient stress is considered an
mTOR dependent autophagy. More recently, it has been
recognized that autophagy is a critical mechanism by
which the host can control the growth of intracellular
pathogens such as mycobacteria [3]. Recognition of the
invading microbe can be achieved through various mecha-
nisms including pattern recognition receptors (NLRs,
TLRs, and sequestome-like receptors), inflammatoryd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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stress [4–8]. Infection of cells with various pathogens and
mTOR inhibition via Rapamycin or nutrient starvation
leads to the isolation of pathogens within autophagosomes
via mTOR dependent autophagy. Fusion of the pathogen-
containing autophagosome with a lysosome to form the
autolysosome results in the direct digestion of the microbe
and the liberation of antigenic epitopes used by MHC-I
and MHC-II to stimulate adaptive immune responses
[9,10]. For example, infection of dendritic cells with myco-
bacteria followed by treatment with Rapamycin enhances
antigen presentation and vaccine efficacy [11]. Moreover,
infection of mice lacking ATG5 with M. tuberculosis, a
protein essential for the processing of LC3B, results in in-
creased bacterial burdens and enhanced inflammatory re-
sponses in comparison to ATG5 expressing mice [12].
Thus, it is essential to better understand how myco-
bacteria may interact with the autophagy pathway so
that enhanced strategies can be designed to improve
autophagy-mediated killing, minimize the risk of disease,
and bolster productive immune responses.
Previous work by our laboratory has documented that
mycobacterial infection naturally induces autophagy in
RAW264.7 cells [13]. mTOR induction by mycobacterial
infection could be blocked by both Rapamycin treatment
and nutrient starvation [13]. However, in contrast to au-
tophagy induced by mTOR inhibition (mTOR dependent
autophagy), mycobacterial infection simultaneously in-
duces both autophagy and mTOR signaling. This indicates
that mycobacteria induce mTOR independent autophagy
responses. These unexpected findings now allow for add-
itional investigation of the relationship between mycobac-
teria, mTOR, and autophagy, which is the basis of our
current work. Our data further supports the notion that
the use of mTOR inhibition to study mycobacterial killing
(mTOR-dependent autophagic killing) is non-physiologic
and thus obscures endogenous biochemistry that is critical
for understanding and exploiting host-pathogen interac-
tions to favor pathogen clearance.
Results
Characterization of mTOR inhibitors
Previous studies have demonstrated that mycobacteria
naturally induce mTOR activity, as measured by P-S6 in-
duction [13]. Additionally, different species of mycobac-
teria induce similar levels of P-S6 (mTOR induction), and
lipids derived from both M. smegmatis and BCG induced
similar levels of P-S6 as well. Rapamycin (1 uM-10 uM)
inhibits P-S6 induction in response to Mycobacterium
bovis Bacille Calmette-Guérin (BCG) while 25 uM Rapa-
mycin was used to confirm the ability of M. smegmatis to
induce mTOR activity. In the current work, we aim to ex-
pand upon previous data and further define the connec-
tion between mTOR inhibition and mycobacterial killing.A panel of mTOR inhibitors that target mTOR kinase dir-
ectly (Torin 1 and Torin 2) or indirectly (Rapamycin) was
chosen to confirm the capacity of these agents to both in-
hibit mTOR activity and to induce autophagy [14].
RAW264.7 cells were pre-treated with either 1 uM or 10
uM of each inhibitor and then challenged with 1 ug/ml
Escherichia coli-derived LPS. All compounds were effect-
ive at both 1 uM and 10 uM concentrations to reduce the
induction of phosphorylated ribosomal S6 (P-S6), a bona
fide mTOR target (Figure 1A). Similarly, Torin 1 and
Torin 2 were effective at inhibiting the induction of P-S6
in response to infection with M. smegmatis (Figure 1B).
Previous studies have shown that Rapamycin can inhibit
P-S6 induction in response to mycobacterial infection.
Treatment of A549 lung epithelial cells with all com-
pounds elicited robust peri-nuclear LC3B puncta forma-
tion, indicating autophagy induction (Figure 1C). A549
cells were chosen to evaluate LCB puncta formation, as
they are large cells that readily permit the visualization of
endogenous puncta, and they are routinely used to study
mycobacterial infection. Lastly, overnight treatment of
RAW264.7 cells loaded with DQ-BSA, a self-quenched re-
porter for proteolysis that correlates well with autophagy
[13,15–18], indicated that all compounds induce DQ-BSA
proteolysis across a wide concentration range (Figure 1D).
While 1 uM Rapamycin did not produce statistically sig-
nificant hydrolysis when compared to untreated cells and
higher doses, a response was nonetheless noted. All other
concentrations of Rapamycin, and all other inhibitors pro-
duced statistically significant DQ-BSA hydrolysis. In sum,
we confirm that Rapamycin, Torin 1, and Torin 2 inhibit
mTOR in response to a bacterial stimulus and induce au-
tophagy. All three compounds are thus suitable for explor-
ing the impact of mTOR inhibition on mycobacterial
survival.
Higher concentrations of mTOR inhibitors are required for
M. smegmatis killing
Since as little as 1 uM of each inhibitor was sufficient to
demonstrate mTOR inhibition and DQ-BSA hydrolysis in
RAW264.7 cells, we evaluated whether equally low con-
centrations of mTOR inhibitors could produce observable
levels of mycobacterial killing. RAW264.7 cells were in-
fected with M. smegmatis and treated with the indicated
mTOR inhibitors at the concentrations shown. M. smeg-
matis was chosen for these assays as this species naturally
induces substantial autophagic responses and thus might
be more sensitive to the additive effects of low dose treat-
ment with mTOR inhibitors [13]. While 1 uM of each in-
hibitor can effectively reduce mTOR signaling, this dose
was insufficient to elicit observable M. smegmatis killing
(Figure 2). Instead, a concentration of 10 uM was required
for a significant loss of M. smegmatis viability for all three
inhibitors in this assay (5 uM dosing produced significant
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Figure 1 Low doses of Rapamycin, Torin 1, and Torin 2 inhibit mTOR and induce autophagy. (A) RAW264.7 cells were pretreated with 1
uM or 10 uM of the mTOR inhibitors indicated and then challenged with 1 ug/ml E. coli derived LPS for 3 hours. Protein lysates were prepared
and western blots for total ribosomal S6 and phosphorylated ribosomal S6 are shown. Shown are data representative of two independent assays
(B) RAW264.7 cells were infected with M. smegmatis (MOI 5) and treated with the mTOR inhibitors shown. Protein lysates were prepared and
western blots for Actin and phosphorylated ribosomal S6 were performed. Shown are data representative of two independent assays (C) A549
cells were treated with 10 uM of the indicated inhibitor for 3 hours and then stained for endogenous LC3B, or an isotype control IgG, and
imaged by fluorescence microscopy. Shown are data representative of two independent assays. (D) RAW264.7 cells were loaded with DQ-BSA,
either left untreated (−DMSO) or treated overnight with the indicated concentrations of the mTOR inhibitors shown, and analyzed by flow
cytometry. Shown is the combined percentage of DQ-BSA positive cells (+/− SEM) and the mean fluorescent intensity (and intensity range)
derived from two independent assays with 3 replicates per assay. For analysis of the percent DQ-BSA positive cells, asterisks indicated p < 0.05 for
drug treated samples versus untreated.
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identify 10 uM as the minimum dose required for robust
mycobacterial killing. Lastly, while not used as extensively
as Rapamycin, Torin 1, and Torin 2, preliminary work
with KU0063794, an additional mTOR inhibitor [19], has
thus far revealed similar mTOR inhibitory properties and
mycobacterial killing capability (data not shown). In sum,
lower doses of Rapamycin, Torin 1, and Torin 2 wereinsufficient to kill M. smegmatis, yet the same doses were
effective at reducing mTOR activity.
Higher concentrations of Rapamycin induce M. smegmatis
killing in LC3B and ATG5 deficient macrophages
Knowing that higher doses of mTOR inhibitors (10 uM
or greater) were essential to produce consistent and ro-


























































































































































































Figure 2 Low doses of Rapamycin, Torin 1, and Torin 2 are insufficient to kill M. smegmatis. RAW264.7 cells were infected with
M. smegmatis and treated with Rapamycin (A), Torin 1 (B), or Torin 2 (C). Cells were then lysed and plated for CFU determination. Shown are
combined results of two independent assays performed with each inhibitor. On the left are the raw CFU values for each replicate. On the right is
the percentage change (+/− SEM) from the mean value of cells treated with DMSO that was set at 100%. For the comparison of raw CFU values,
asterisks indicate p≤ 0.05 for drug treated groups versus DMSO treated cells.
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hibition was autophagy specific or due to an unrecognized
secondary effect. Similar killing assays were performed in
LC3B and ATG5 [20,21] deficient macrophages. Rapamycin
was chosen for these assays, as it is the most widely used
mTOR inhibitor and its mycobacterial killing properties
was comparable to the Torin compounds. We began by
first testing C57BL/6 BMDMs to confirm successful differ-
entiation of wildtype macrophages capable of killing M.
smegmatis. As shown in Figure 3A, both 25 uM and 50 uM
of Rapamycin could successfully induce killing in infected
C57BL/6 macrophages. Concentrations of 25 uM and
50 uM were chosen based on the observation that at least
10 uM Rapamycin is required for consistent and robustkilling in RAW264.7 cells as shown in Figure 2. As a result,
25 uM and 50 uM doses were chosen to guaranteeM. smeg-
matis killing in these assays. Similar assays were independ-
ently applied to LC3B and ATG5 deficient macrophages. It
has been established that ATG5 is critical for efficient au-
tophagic responses to mycobacteria, and that LC3B coated
vesicles co-localized with mycobacteria to deliver toxic pay-
loads [5,12,22,23]. Therefore, the goal was to determine how
treatment with 25 uM and 50 uM Rapamycin would impact
bacterial viability in both mouse models. Treatment of
LC3B and ATG5 deficient macrophages with 25 uM and 50
uM Rapamycin yielded observable killing in comparison to
Rapamycin untreated macrophages (Figure 3B and C). To
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Figure 3 High doses of Rapamycin can kill M. smegmatis in wildtype and autophagy deficient macrophages. (A) Bone marrow derived
macrophages from C57BL/6 mice were infected with M. smegmatis and treated with the indicated concentrations of Rapamycin. The cells were
lysed and CFU was determined as described in Figure 2. (B-C) Bone marrow derived macrophages from B6.129 LC3KO mice and B6 LysM-ATG5
mice were isolated and treated as described above. For parts (A-C), shown are results representative of two independent assays per mouse strain.
(D) Western blot of protein lysates of samples described in (A) and (B) for ribosomal S6 and phosphorylated ribosomal S6. Asterisks indicate
p≤ 0.05 drug treated groups versus DMSO treated cells.
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to Rapamycin, western blots from infected cells with or
without Rapamycin treatment were performed. As expected,
LC3B deficient macrophages could induce P-S6 in response
to M. smegmatis, and P-S6 induction was blocked by
Rapamycin (Figure 3D). We conclude that the ability of
higher doses of Rapamycin to induce mycobacterial killing
is at least LC3B and ATG5 independent and that a defi-
ciency in the canonical autophagy pathway does not alter
mTOR signaling in response to mycobacterial infection.
M. smegmatis and BCG are not directly impacted by
Rapamycin in the context of a typical autophagy assay
The observation that higher of doses of mTOR inhibitors
were required to elicit robust mycobacteria killing in
RAW264.7 cells led us to suspect that Rapamycin might
directly impact mycobacteria in autophagy assays. To test
this hypothesis, a modified autophagy assay was performed
whereby RAW264.7 cells were eliminated from the assay.
M. smegmatis and BCG were cultured in DMEM contain-
ing 10% HI-FBS under mammalian cell conditions with ei-
ther DMSO (control) or Rapamycin. After 3 hours, the
cultures were harvested and the mycobacteria were plated
for CFU determination. As shown in Figure 4A and B, nei-
ther M. smegmatis nor BCG viability was impacted byRapamycin in these assays when cultured with up to 25 uM
Rapamycin. We conclude that Rapamycin does not appear
to directly impact the mycobacteria tested during a stand-
ard autophagy assay condition in the absence of the host
cells.
Long-term exposure to Rapamycin can impact the growth
of some mycobacterial species
It has been reported that Rapamycin can attenuate the
growth of Mycobacterium avium subspecies paratuberculo-
sis (MAP) [24]. While the short-term growth of M. smeg-
matis does not appear to be altered by Rapamycin, we
wondered if longer exposures of Rapamycin could alter the
growth properties of mycobacteria. Several species of myco-
bacteria were exposed to Rapamycin for longer durations in
their typical growth media (7H9-OADC) and the OD600
was monitored for changes in culture growth. M. smegma-
tis, which is a non-pathogenic, fast-growing mycobacter-
ium, was not impacted by Rapamycin through 10 hours of
exposure (Figure 5A). In contrast, both BCG and Mycobac-
terium kanasii, which are non-pathogenic, slow-growing
mycobacteria, failed to reach an OD600 of 1.0 after over
100 hours of culture (Figure 5B). While somewhat unex-
pected, the Rapamycin-induced growth inhibition observed




















































































































Figure 4 Rapamycin does not kill M. smegmatis or BCG in the absence of macrophages. M. smegmatis (A) or BCG (B) were cultured in
DMEM+DMSO (control) or the indicated doses of Rapamycin. After 3 hours at 37C and 5% CO2, the wells were mixed and the bacteria were plated
for CFU determination. On the left are the raw CFU values for each replicate. On the right is the percentage change (+/− SEM) from the mean value of
cells treated with DMSO, which was set at 100%. For both (A) and (B), shown are the combined results of two independent assays.
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were performed with M. tuberculosis H37Rv, a common la-
boratory strain, as well as M. tuberculosis clinical isolates.
While the growth properties of all pathogenic mycobacteria
were altered at later time-points (> 100 hours) as indicated
by Student’s T test, the magnitude of the differences was
modest. There was however no differences observed at
shorter time-points (Figure 5C). Thus, it is unlikely that
Rapamycin has a direct effect on mycobacterial growth dur-
ing standard autophagy assays, but it can alter growth after
prolonged exposures in some mycobacterial species.
Discussion
The autophagy pathway has emerged as a versatile cellu-
lar mechanism that allows mammalian cells to defend
themselves from an array of intracellular microbes [7,9].
Autophagy induction through mTOR inhibition is widely
used to demonstrate the autophagic killing of a wide var-
iety of pathogens including mycobacteria. This mTOR
dependent autophagy triggers an evolutionarily conserved
autophagy response that mimics nutrient deprivation.
While extremely effective at inducing pathogen killing,
inhibiting mTOR activity may not faithfully recapitulate
the biochemistry induced during infection. This is exem-
plified by previous work from our laboratory demonstrat-
ing that mycobacterial infection simultaneously induces
both autophagy and mTOR signaling [13]. While largelyunexpected, these initial findings now permit additional
query into the relationship between mTOR inhibition and
pathogen killing.
In the current work, we show that while 1 uM of the
mTOR inhibitors Rapamycin, Torin 1, and Torin 2 could
reduce mTOR activity, (Figure 1 and previously pub-
lished), at least 10 uM of the inhibitors were required to
demonstrate consistent and significant killing of M.
smegmatis in RAW264.7 macrophages (Figure 2). This
trend of higher concentrations of mTOR inhibitors be-
ing required for observable mycobacterial killing appears
to exist for both allosteric (Rapamycin) and active site
inhibitors (Torin 1 and Torin 2) of mTOR. This is an
unexpected result as M. smegmatis infection naturally in-
duces substantial autophagy responses such that the kin-
etic balance should favor killing at lower levels of mTOR
inhibition [13]. These findings inspired us to ask if the
mycobacterial killing observed with high doses of Rapamy-
cin can occur in macrophages devoid of canonical autoph-
agy components. Using LC3B and ATG5 deficient
BMDMs that lack the structural formation of autophago-
somes, we showed that 25 uM and 50 uM Rapamycin act
through an unappreciated mechanism to induce killing, not
through LC3B or ATG5 dependent autophagy (Figure 3).
Moreover, a deficiency in the autophagy pathway does not
appear to alter mTOR signaling in response to mycobacter-












































































































































Figure 5 Long incubations with Rapamycin can alter the growth of some mycobacterial species. (A) Fast-growing M. smegmatis was
grown in 7H9 + OADC in the presence of either DMSO (control) or Rapamycin (10 uM). Shown is the OD600 (+/− SEM) at the time intervals
described of 7 replicate cultures from 2 independent experiments. The last time point for each growth curve comparing DMSO treatment versus
Rapamycin treatment was compared by Student’s T test and found non significant (NS). (B) Slow-growing BCG and M. kanasii were grown in
7H9 + OADC in the presence of either DMSO (control) or Rapamycin (10 uM). Shown is the OD600 (+/− SEM) at the time intervals described of
10 replicate cultures from 2–3 independent experiments per species. The last time points for each growth curve comparing DMSO treatment
versus Rapamycin treatment were compared by Student’s T test. Asterisks indicate p < 0.05. (C) The indicated pathogenic mycobacterial species
were grown in 7H9-OADC in the presence of DMSO (control) or Rapamycin (10 ug/ml). A laboratory strain (H37Rv), KZN drug-sensitive strain
(V9124 [S]), a multidrug resistant (MDR) strain (V2475 [M]), and an extensively drug resistant (XDR) strain (TF275 [X]) were used. Shown is the
OD600 (+/− SEM) at the time intervals described of 7–8 replicates from 2 independent experiments. The last time points for each growth curve
comparing DMSO treatment versus Rapamycin treatment were compared by Student’s T test. Asterisks indicate p < 0.05.
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mTOR, could compensate when such a strong stimulus is
applied, we must assume that additional autophagic and
unidentified cellular responses become involved as the dose
of Rapamycin increases. The prospect of additional cellular
mechanisms that kill mycobacteria, and are induced upon
mTOR inhibition, is an exciting possibility that warrants
further investigation.
Since Rapamycin has long been known for its antibiotic
properties in fungi and more recently in MAP (Mycobac-
terium avium subspecies paratuberculosis) [24], it seemed
plausible that Rapamycin may have a direct impact on
mycobacteria themselves at higher concentrations. As
shown in Figure 4, it is unlikely that within the short time
course of a standard autophagy assay that these chemicals
could directly interfere with mycobacteria to preclude
their viability. The observation that macrophages are re-
quired for killing indicates that one or more cellular
mechanisms are required for mycobacterial killing under
the short time frames and conditions of an autophagy
assay. Interestingly, we did observe that certain strains of
mycobacteria, such as BCG, M. kanasii, and laboratory
and clinical isolates of M. tuberculosis, did have altered
growth properties when exposed to Rapamycin for ex-
tended periods of time (Figure 5). While not related to
autophagy per se, the data suggests there may be an
unrecognized inhibitory target in mycobacteria that ex-
hibits sensitivity to Rapamycin. Additional work in this
area will seek to identify this target, utilizing Rapamycin
as a foundation, in an effort to design more mycobacter-
ium specific compounds.
Throughout this study we utilized the phosphorylation
of ribosomal S6 protein (P-S6) as the indicator of mTOR
activity in our assays. While this is a well-known and
highly bona fide mTOR target that has been widely uti-
lized as a measure of mTOR activity [13,25], we cannot
rule out that other, and perhaps unknown, mTOR targets
are better correlates of mycobacterial killing in autophagy
assays that utilize mTOR inhibition. This is an exciting
idea, since it suggests that there are unrecognized mTOR
targets that have a direct connection to mycobacterial in-
fection whose activity is not altered by lower levels of
mTOR inhibitors. Proteomics approaches will be required
to take an unbiased approach to this question and identify
the full spectrum of mTOR targets that are impacted by
mycobacterial infection in the presence and absence of
various concentrations of mTOR inhibitors.
The use of mTOR inhibitors to induce mTOR dependent
autophagic pathogen killing has become the gold-standard
assay within the autophagy field. This is somewhat counter-
intuitive given that nutrient sensing and pathogen sensing
utilize unique, and presumably non-overlapping, biochem-
ical mechanisms to affect stimulus specific responses.
Taken in sum, our current work strongly suggests that theuse of mTOR dependent autophagy to study mycobacterial
killing (and possibly other pathogen killing) is artificial and
casts shadows on the endogenous host-pathogen biochem-
istry that naturally occurs during infection. This is consist-
ent with our previous studies indicating that mycobacteria
induce mTOR independent autophagy during infection. Fu-
ture efforts on our part will continue to study mycobacter-
ial autophagy in the absence of artificial influences/inducers
to identify specific biochemical events that can be exploited
to bolster host defenses. This could be accomplished by a
number of methodologies including: proteomics ap-
proaches that identify specific post-translational modifica-
tions induced shortly after mycobacterial infection; the
identification of mycobacterial transposon mutants that are
susceptible to macrophage autophagy; the continued use of
newly created mouse model systems that are more or less
susceptible to mycobacterial infection; and the identifica-
tion of pharmacological agents that induce autophagy and
mycobacterial killing without inhibiting the immunologic-
ally sensitive mTOR pathway. Lastly, while mTOR inhib-
ition does carry with it substantial global effects on cellular
metabolism, it can not be overlooked that finely tuned
mTOR inhibition, especially if restricted to macrophages
(alveolar for example), could provide a valuable means to
favor host defense against mycobacterial infection.
Conclusions
While low doses of several mTOR inhibitors are sufficient
to reduce mTOR signaling as measured by a reduction in
phosphorylated ribosomal S6, the same doses of these
compounds are incapable of eliciting robust killing of M.
smegmatis. In contrast, high doses of Rapamycin, the most
common mTOR inhibitor used in autophagy research, in-
duces substantial M. smegmatis killing in wildtype macro-
phages and macrophages from autophagy deficient mice.
As it does not appear that Rapamycin has a direct effect
on mycobacteria in the short time frames of standard au-
tophagy assays, it suggests that high dose inhibition of
mTOR may be acting through an unappreciated cellular
mechanism to elicit killing activity. When combined with
our previous studies demonstrating that mycobacterial in-
fection naturally induces both autophagy and mTOR sig-
naling, this data reinforces the idea that mTOR inhibition
through drugs or starvation is an artificial means of study-
ing mycobacterial killing. We contend that the use of
mTOR inhibition to study the molecular mechanisms of
host-pathogen interactions is masking the relevant bio-
chemistry that needs to be understood and exploited to
favor host defense. However, additional studies further
examining the connection between mycobacteria, the
mTOR pathway, and host defense need to be performed,
as fine-tuning mTOR activity to favor host defense with-
out additional effects would be advantageous and could be
developed as a valuable therapeutic.
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Mice
Wildtype and LC3B knockout mice [20,21] were purchased
from Jackson laboratories. LysM-ATG5 mice were a gener-
ous gift from Herbert Virgin (Washington University). All
mice were housed in the Duke Human Vaccine Institute
Regional Biocontainment laboratory in accordance with in-
stitutional animal care and use guidelines.mTOR inhibitors
Rapamycin (Sigma), Torin 1, and Torin 2, (Tocris) were
dissolved in DMSO to a concentration of 10 mM, ali-
quoted, and stored at −20°C. Inhibitors were diluted
fresh in culture media immediately before use. Lipopoly-
sacharride (LPS) was purchased from Sigma, dissolved
in DMEM, aliquoted, and stored at −20°C.Mycobacteria
Mycobacterium bovis Bacille Calmette-Guérin (BCG)
and M. smegmatis have been described previously [13].
This study also uses a KZN drug-sensitive strain (V9124
[S]), a multidrug resistant (MDR) strain (V2475 [M]),
and an extensively drug resistant (XDR) strain (TF275
[X]). All KZN strains were recovered from patients in
KwaZulu-Natal province, South Africa [26]. Unless
otherwise noted, mycobacterial strains were cultured in
7H9 media containing 0.5% glycerol, 0.05% tyloxapol,
and 10% OADC (Oleic Acid, Albumin, Dextrose, Cata-
lase supplement; hereinafter termed “7H9-OADC”).Cell culture, infection, and mycobacterial survival
Murine RAW264.7 macrophages have been described pre-
viously [13]. Cells were cultured in DMEM supplemented
with 10% heat-inactivated fetal bovine serum (HI-FBS), L-
glutamine, sodium pyruvate, and non-essential amino
acids. Human A549 alveolar epithelial cells were cultured
in RPMI 1640 supplemented with 10% FBS, 1% sodium
pyruvate, 1% HEPES and 1% of both non-essential and es-
sential amino acids. For infections, mycobacteria growing
in 7H9-OADC were washed in PBS with 0.05% tyloxapol,
sonicated to minimize bacterial clumping, and adjusted to
the multiplicity of infection 5 (MOI-5). RAW264.7 cells
were first infected with mycobacteria, chemical inhibitors
were added for the indicated periods of time, and CFU
was then determined [13]. For assays involving bone mar-
row derived macrophages (BMDM), the bone marrow was
isolated and depleted of red blood cells. The cells were
then differentiated toward the macrophage lineage with
DMEM media supplemented with L929 derived culture
supernatant [27]. Infection and CFU determination were
performed as described above.Western blots
The following antibodies were used in this study: anti-
Actin plus anti-mouse HRP were purchased from Gen-
Script and Anti-phospho-S6, anti-S6, and anti-rabbit-HRP
were purchased from Cell Signaling. Blotting conditions
and chemiluminescence have been described [13].
DQ-BSA assays and flow cytometry
RAW264.7 macrophages were loaded with DQ-BSA as
described previously [13]. After an overnight treatment
with mTOR inhibitors, DQ-BSA was detected utilizing
the PE channels of a BD FACSCanto or a BD LSRII flow
cytometer. Flow cytometry was performed at both the
Duke University Shared Cytometry Resource and the
Yale School of Medicine Cell Sorter Facility. The data
were analyzed with FlowJo software.
LC3 Immunofluorescent staining
A549 cells were cultured on glass coverslips, fixed with
4% formalin, stained with either rabbit anti-LC3B (Cell
Signaling) or isotype control, and visualized with Alexa
Fluor-594 conjugated anti-rabbit secondary antibodies as
described [28]. Counter-staining with Hoechst, fluores-
cent microscopy, and image analysis were performed as
described previously [13,28].
Statistics
Analysis was performed with GraphPad Prism using an
analysis of variance (ANOVA) with a Tukey post-test or
Students T test. P values of p ≤ 0.05 were considered to
be significant.
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